AF
BDTX icon

Amalgamated Financial’s Black Diamond Therapeutics BDTX Stock Holding History

Amalgamated Financial’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$8K Buy
+2,742
New +$10K ﹤0.01% 2922

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's BDTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Black Diamond Therapeutics (BDTX) in Q1 2022: 2,742 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2922 among its holdings.

87 funds tracked by Wall St. Rank hold BDTX as of Q1 2022.

  • Amalgamated Financial held 2,742 shares of Black Diamond Therapeutics worth $8K as of Q1 2022.
  • Black Diamond Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Black Diamond Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2922 holding.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.